Agreements reached under this partnership
Business alliance- 1
Exclusive distribution in Japan of products and services provided by Epigenome
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this matter on the current fiscal year's results of the company as a whole is minor.
| Item | Details |
|---|---|
| Name of alliance partner | Epigenome Technologies |
| Alliance partner's business activities | Provision of epigenetics-related products and services |
| Alliance partner's location | California, United States |
| Type of alliance | Business alliance |
| Details of the alliance | Exclusive distribution in Japan of products and services provided by Epigenome |
| Contract Date | 13 August 2026 |
| Alliance start date | September 2026 (scheduled start of sales) |
| Impact on Business Performance | The impact of this matter on the current fiscal year's results of the company as a whole is minor. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Amid growing demand for single-cell multi-omics analysis, the agreement will enable the company to broadly provide Epigenome Technologies' products and services to pharmaceutical companies, biotechnology companies, universities and other research institutions in Japan, thereby contributing to the advancement of life sciences research in Japan.